Advanced search
Publication Cover
Gynecological Endocrinology Volume 35, 2019 - Issue 5
Submit an article Journal homepage
2,412
Views
4
CrossRef citations to date
0
Altmetric
PREMENSTRUAL SYMPTOMS AND ORAL CONTRACEPTIVES

Changes in premenstrual symptoms in women starting or discontinuing use of oral contraceptives

Linda EkenrosDepartment of Neurobiology, Care Science and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden; Correspondence[email protected]
,
Torbjörn BäckströmDepartment of Clinical Science, Obstetrics and Gynecology, Umeå University, Umeå, Sweden;
,
Angelica Lindén HirschbergDepartment of Women’s and Children’s Health, Karolinska Institutet, Huddinge, Sweden; ;Department of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden
&
Cecilia FridénDepartment of Neurobiology, Care Science and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden;
Pages 422-426 | Received 04 Jun 2018, Accepted 06 Oct 2018, Published online: 22 Jan 2019

References

  • Sveinsdóttir H, Bäckström T. Menstrual cycle symptom variation in a community sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand. 2000;79:757–764.
  • Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371:1200–1210.
  • Bäckström T, Andreen L, Birzniece V, et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs. 2003;17:325–42.
  • Freeman EW, Rickels K, Sondheimer SJ, et al. Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes. J Clin Psychopharmacol. 2001;21:540–542.
  • Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257–266.
  • Abraham S, Luscombe G, Soo I. Oral contraception and cyclic changes in premenstrual and menstrual experiences. J Psychosom Obstet Gynaecol. 2003;24:185–193.
  • Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.
  • Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501.
  • Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–421.
  • Zethraeus N, Dreber A, Ranehill E, et al. A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial. Fertil Steril. 2017;107:1238–1245.
  • Bäckström T, Hansson-Malmström Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992;46:253–268.
  • Sundström I, Nyberg S, Bixo M, et al. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand. 1999;78:891–899.
  • Ekenros L, Hirschberg AL, Bäckström T, et al. Postural control in women with premenstrual symptoms during oral contraceptive treatment. Acta Obstet Gynecol Scand. 2011;90:97–102.
  • Pearlstein T, Yonkers KA, Fayyad R, et al. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005;85:275–282.
  • Zethraeus N, Dreber A, Ranehill E, et al. Combined oral contraceptives and sexual function in women-a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2016;101:4046–4053.
  • Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993;37:195–202.
  • Nyberg S. Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol. Contraception. 2013;87:773–781.
  • Greco T, Graham CA, Bancroft J, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception. 2007;76:8–17.
  • Freeman EW, Halbreich U, Grubb GS, et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85:437–445.
  • Sanders SA, Graham CA, Bass JL, et al. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58.
  • Josefsson A, Wiréhn AB, Lindberg M, et al. Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010. BMJ Open. 2013;3:e003401.
  • Nassaralla CL, Stanford JB, Daly KD, et al. Characteristics of the menstrual cycle after discontinuation of oral contraceptives. J Womens Health. (Larchmt) 2011;20:169–177.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.